does Cartalax repair human cartilage?
the exact Ala-Glu-Asp tripeptide has cell-culture activity and a sparse human patent example. neither demonstrates repaired human cartilage.
verdict: cell activity real, cartilage-repair claim unsupported (preclinical plus poorly reported patent evidence)
quick answer
peer-reviewed human-cell studies report gene-expression and aging-marker changes. An assignee patent describes 29 people with knee osteoarthrosis and 12 saline controls, but it omits enough group-level and statistical detail that it cannot establish cartilage repair, and it reports no significant radiographic dynamics.
the evidence
AED changes measured cell markers. (supported)
Human mesenchymal stem-cell and skin-fibroblast cultures show changes in aging-related gene expression, MMP-9, proliferation, and apoptosis markers.
the human example is poorly reported. (gap)
The patent says 29 participants were randomly divided and identifies 12 saline controls, but omits active-subgroup sizes, clear blinding and attrition, adequate group comparisons, adverse-event detail, and sufficient statistics.
symptom change does not prove cartilage regeneration. (contradicted)
The patent reports no significant radiographic dynamics, and no independent peer-reviewed replication was located. The structural repair claim remains unsupported.
bottom line
pain or movement reports are not structural cartilage regeneration.
scores
- chemical identity: 88 — exact AED tripeptide is traceable
- cell mechanism: 64 — peer-reviewed expression studies
- human outcomes: 20 — sparse assignee-patent example
- cartilage repair proof: 4 — no adequate structural outcome or replication
keep reading
- open Cartalax entry — identity, patent, and cell evidence
- healing category — outcome-ranked repair claims
- Cartalax vs BPC-157 — cartilage and repair evidence contrast
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.
